Yes, hi. Congratulations, Ritesh, on a strong guidance. Two questions. First of all, this BPAS healthcare deal, has it ramped up to its peak potential or do we still have some revenue to be expected in the first half of 27?
The reason I asked this is, Ritesh, because this quarter our growth was predominantly led by healthcare vertical which grew 10% to 11%. So was just checking whether this BPAAS deal ramp-up was a good contributor to growth?
Congratulations on a great quarter again. A couple of questions. First is if I look at the revenue growth number it looks a bit muted despite a 200 bps increase in our on -site revenue contribution. Just some clarification there?
And another question here is, last quarter, you had indicated that on revenue growth to some extent...
Couple of questions here, Angan. First is we've seen very solid growth in our top 6 to 10 clients bucket. So, was it led by some particular account in that bucket or was it some widespread growth that you've seen in that band?
Right. And in terms of margins, if I look at the segmental margins, margins in Life Sciences have seen a sharp decline on a Q-on-Q basis. So, barring the Invacare adjustment, is there anything else to read into it?